GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Absci Corp (NAS:ABSI) » Definitions » Total Liabilities

Absci (ABSI) Total Liabilities : $34.79 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Absci Total Liabilities?

Absci's Total Liabilities for the quarter that ended in Mar. 2024 was $34.79 Mil.

Absci's quarterly Total Liabilities increased from Sep. 2023 ($39.93 Mil) to Dec. 2023 ($41.12 Mil) but then declined from Dec. 2023 ($41.12 Mil) to Mar. 2024 ($34.79 Mil).

Absci's annual Total Liabilities declined from Dec. 2021 ($60.09 Mil) to Dec. 2022 ($46.59 Mil) and declined from Dec. 2022 ($46.59 Mil) to Dec. 2023 ($41.12 Mil).


Absci Total Liabilities Historical Data

The historical data trend for Absci's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Absci Total Liabilities Chart

Absci Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
60.63 178.00 60.09 46.59 41.12

Absci Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.84 38.75 39.93 41.12 34.79

Absci Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Absci's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=29.558+(10.379+0.033000000000001
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+1.152+0)
=41.12

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=217.298-176.176
=41.12

Absci's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=25.288+(9.07+0.077999999999996
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0.355+0)
=34.79

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=274.898-240.107
=34.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Absci Total Liabilities Related Terms

Thank you for viewing the detailed overview of Absci's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Absci (ABSI) Business Description

Traded in Other Exchanges
N/A
Address
18105 SE Mill Plain Boulevard, Vancouver, WA, USA, 98683
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Executives
Frans Van Houten director 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Daniel A Rabinovitsj director 400 W CESAR CHAVEZ, AUSTIN TX 78701
Andreas Busch director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Sarah Korman officer: General Counsel 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98660
Todd Bedrick officer: VP, CCPAO 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Joseph Sirosh director C/O COMPASS, INC., 155 AVENUE OF THE AMERICAS, SIXTH FLOOR, NEW YORK NY 10013
Sean Mcclain director, 10 percent owner, officer: President and Chief Executive 18105 SE MILL PLAIN BLVD, SUITE 350, VANCOUVER WA 98683
Zachariah Jonasson director 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Eli Casdin director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Master Fund, L.p. director, 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Karen K Mcginnis director INSIGHT ENTERPRISES INC, 1305 WEST AUTO DRIVE, TEMPE AZ 85284
Redmile Biopharma Investments Ii, L.p. director, 10 percent owner LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129
Phoenix General Partner Ii Llc 10 percent owner 1700 S. EL CAMINO REAL, SUITE 335, SAN MATEO CA 94402
Nikhil Goel officer: Chief Business Officer 101 E. 6TH STREET, SUITE 350, VANCOUVER WA 98660